ChemGenex Pharmaceuticals will gain full commercial control of omacetaxine mepesuccinate (formerly known as Ceflatonin) through an arrangement with its European partner Stragen Pharma to transfer the ownership of Intellectual Property (IP) and commercial rights currently held by Stragen.
Omacetaxine is ChemGenex's lead product in clinical development and is in the final stages of a phase 2/3 clinical trial in chronic myeloid leukaemia (CML) patients with the T315I mutation for whom there are currently no effective drug treatments.
The details can be read here.
No comments:
Post a Comment